title: [Clinical approach to primary membranoproliferative glomerulonephritis].
abstract: Membranoproliferative glomerulonephritis represent a heterogeneous group of nephropathies. During the last five years, our understanding of membranoproliferative glomerulonephritis has greatly improved. Animal models and the study of complement genetics led to the dissection of the physiopathology of membranoproliferative glomerulonephritis, to the individualization of a new entity, C3 glomerulopathy, and to a new classification of these nephropathies. The study of large cohorts has also changed the clinical picture of membranoproliferative glomerulonephritis that has been long dominated by the severity of a single type of dense deposits disease. Finally, the rediscovery of complement through the study of the atypical haemolytic uremic syndrome and the availability in clinical practice of complement inhibitors have paved the way for new therapeutic approaches of membranoproliferative glomerulonephritis.
authors.affiliation: Service de néphrologie et d'immunologie, CHU de Nantes, 1, place Alexis-Ricordeau, 44000 Nantes, France; Inserm UMR S-1064, 30, boulevard Jean-Monnet, 44093 Nantes cedex 01, France; Institut de transplantation urologie-néphrologie (Itun), 30, boulevard Jean-Monnet, 44093 Nantes cedex 01, France. Electronic address: fadi.fakhouri@univ-nantes.fr.
authors.forename: Fadi
authors.initials: F
authors.lastname: Fakhouri
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003176:Complement C3; D003178:Complement C3 Nephritic Factor; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D015432:Glomerulonephritis, Membranoproliferative / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D009173:Mycophenolic Acid / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003176:Complement C3; D003178:Complement C3 Nephritic Factor; D004791:Enzyme Inhibitors; C481642:eculizumab; D009173:Mycophenolic Acid
keywords: Complement; Complément; Dense deposits; Dépôts denses; GMNP; Genetics; Génétique; MPGN